Press Releases

Date Title
May 26, 2020
Outlook Therapeutics Announces $16.0 Million Private Placement to Advance the Development of ONS-5010 / LYTENAVA™ (bevacizumab-vikg)
Strategic investment at a premium enhances Company’s ongoing development activities of ONS-5010 / LYTENAVA™ (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab to treat wet AMD, toward FDA approval   Syntone and Outlook to form joint venture to develop and commercialize
May 15, 2020
Outlook Therapeutics Reports Financial Results for the Second Quarter of Fiscal Year 2020 and Provides Corporate Update
Company remains on track to report topline data results from NORSE 1, its first registration clinical trial evaluating ONS-5010, an investigational ophthalmic formulation of bevacizumab to treat wet AMD, in August 2020   Enrollment in NORSE 2 registration clinical trial remains ongoing and is
April 21, 2020
Outlook Therapeutics Bolsters Clinical and Commercial Expertise with Two Key Appointments to Board of Directors
Internationally renowned ophthalmologist, Gerd Auffarth , MD, ranked as one of the “100 most influential personalities in ophthalmology worldwide" in the 2020 Power List published by The Ophthalmologist  magazine Julian Gangolli , former President of the North American Pharmaceutical division of
April 15, 2020
Outlook Therapeutics to Present at the April 2020 Virtual Investor Summit
Presentation with live audio webcast on Wednesday, April 22 at 10:30 AM ET, immediately followed by an interactive Q&A session CRANBURY, N.J. , April 15, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to
April 14, 2020
Outlook Therapeutics Provides COVID-19 Impact Update on Ongoing Clinical Trials NORSE 1 and NORSE 2
Company reports no anticipated COVID-19 impact on NORSE 1, its first registration clinical trial evaluating ONS-5010, an investigational ophthalmic formulation of bevacizumab, to treat wet AMD   Risk mitigation strategies being developed for possible one- to three-month delay related to COVID-19
March 5, 2020
Outlook Therapeutics Announces LYTENAVA™ (bevacizumab-vikg), Anticipated Brand Name for ONS-5010, If Approved
Outlook Therapeutics intends to market ONS-5010 as LYTENAVA ™  (bevacizumab-vikg), if approved. LYTENAVA™ (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for retinal indications, is currently in two registration clinical trials (NORSE 1 and NORSE 2) to treat wet
February 26, 2020
Outlook Therapeutics Announces Closing of $10.2 Million Financings Priced At-The-Market
CRANBURY, N.J. , Feb. 26, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that it has
February 24, 2020
Outlook Therapeutics Announces $10.2 Million Financings Priced At-The-Market
CRANBURY, N.J. , Feb. 24, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that it has
February 14, 2020
Outlook Therapeutics Provides Business Update and Reports Financial Results for the First Quarter of Fiscal Year 2020
First clinical trial results from the Phase 3 development program for ONS-5010 expected in six months CRANBURY, N.J. , Feb. 14, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA
February 4, 2020
Outlook Therapeutics to Present at the 2020 BIO CEO & Investor Conference
CRANBURY, N.J. , Feb. 04, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”),  a late clinical-stage biopharmaceutical company working to develop the first FDA -approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that it is
Displaying 1 - 10 of 81